ASH 2018 | Early look at data for CAR-T bb21217 in R/R MM
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
bb21217 is a next-generation anti-BCMA CAR T-cell therapy, which has shown promising results for the treatment of relapsed/refractory multiple myeloma (MM). Here, Noopur Raje, MD, of Massachusetts General Hospital, Boston, MA, discusses the safety and efficacy of bb21217 from the Phase I dose escalation CRB-402 trial (NCT03274219) that was presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up